Edmund Ingham is an Investing Group Leader at Haggerston BioHealth. He has been covering biotech, healthcare, and pharma for over 5 years, focusing on investment strategies and alternative investments within these sectors. Edmund is featured in Seeking Alpha.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Edmund Ingham's articles predominantly focus on investment analysis, particularly in the finance and healthcare & pharmaceutical sectors. Given this, he is likely to be most responsive to pitches that offer expert insights into stock performance, company earnings reports, or detailed financial analysis within these industries.
Considering his extensive use of data and statistics in his coverage attributes, Edmund would likely appreciate pitches from sources who can provide credible quantitative analysis related to stock performances or trends within the pharmaceutical and biotech sectors.
While no specific geographic focus is mentioned for Edmund’s articles, it seems that he covers global companies listed on major exchanges like NYSE. Therefore, pitching international perspectives backed by relevant data could be beneficial when reaching out to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Edmund Ingham
Lexicon Pharmaceuticals is downgraded to Hold after a 40% stock rally, reflecting heightened uncertainty across its pipeline. Read more on LXRX stock here.
By: Edmund Ingham
Summary Corbus Pharmaceuticals Holdings, Inc. stock plunged after updated CRB-701 Phase 1/2b data in OPSCC and cervical cancer failed to impress the market.
Summary Biohaven Ltd. shared an R&D presentation today in relation to its epilepsy asset and also updated on its degrader programs.
By: Edmund Ingham
Summary Ionis Pharmaceuticals remains a Buy, with a compelling bull case despite a >125% 12-month share price increase.
By: Edmund Ingham
Personalis, Inc. is rated Buy, driven by strong momentum in its NeXT Personal Dx MRD test and recent Medicare coverage expansions.
Summary Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data expected mid-2026.
By: Edmund Ingham
Summary Intellia Therapeutics remains a Buy, driven by two pivotal in vivo gene therapy catalysts: Lonvo-Z for HAE and Nex-Z for ATTR amyloidosis.
By: Edmund Ingham
Summary Elevance Health, Inc. has rebounded ~34% from its March lows, supported by sector recovery and improved Q1 2026 results.
By: Edmund Ingham
Oculis Holding AG shares plunged >35% after both Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed primary and key secondary endpoints.
By: Edmund Ingham
Summary Revolution Medicines, Inc. has delivered unprecedented Phase 3 data for daraxonrasib in second-line metastatic pancreatic cancer, nearly doubling overall survival versus chemotherapy.
